IPF Patients Benefit from Pirfenidone Treatment

IPF Patients Benefit from Pirfenidone Treatment


An analysis of pooled data from three Phase 3 clinical trials in idiopathic pulmonary fibrosis (IPF) patients shows that treatment with pirfenidone for one year significantly reduced disease progression. The study, titled “Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials,” was published in the European Respiratory Journal.

Pirfenidone (Esbriet, developed by Genentech, Roche) is an oral antifibrotic agent tested as a treatment for IPF in three multinational Phase 3 clinical trials: two CAPACITY trials, investigating pirfenidone’s efficacy and safety as a therapy for at least 72 weeks, and the ASCEND trial, which evaluated treatment with pirfenidone for 52 weeks.

Read more about it: http://bit.ly/1meAarp

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *